US68232V8019 - Common Stock
TRAWS PHARMA INC
NASDAQ:TRAW (9/6/2024, 8:00:02 PM)
After market: 0.3502 -0.01 (-3.26%)0.362
+0.01 (+2.26%)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The firm is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
TRAWS PHARMA INC
12 Penns Trail
Newtown PENNSYLVANIA
P: 12677593680
Employees: 16
Website: https://www.onconova.com/
Traws Pharma just reported results for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traws Pharma (NASDAQ:TRAW) just reported results for the second quarter of 2024...
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations...
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing...
Here you can normally see the latest stock twits on TRAW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: